
Pharmaceuticals · TSE: 4568
Daiichi Sankyo earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends March · next results expected around 30 Jul 2027
Latest: Q2 FY2026
Daiichi Sankyo is scaling Enhertu and Datroway through new first-line approvals, a Summit Therapeutics combination deal and a single global commercialization unit launching April 2027.
Enhertu became the US market leader in first-line HER2-positive metastatic breast cancer and took the top share in adjuvant early breast cancer. Datroway has treated about 9,800 patients globally, roughly 1.4 times the prior quarter, and leads later-line EGFR-mutated lung cancer in the US. New approvals landed across the US, Europe, Japan and China. Non-oncology units such as American Regent and Lixiana were weaker.
Quarters
KPI history